Literature DB >> 25480730

Characterization of 28 novel patients expands the mutational and phenotypic spectrum of Lowe syndrome.

Florian Recker1, Marcin Zaniew, Detlef Böckenhauer, Nunzia Miglietti, Arend Bökenkamp, Anna Moczulska, Anna Rogowska-Kalisz, Guido Laube, Valerie Said-Conti, Belde Kasap-Demir, Anna Niemirska, Mieczysław Litwin, Grzegorz Siteń, Krystyna H Chrzanowska, Małgorzata Krajewska-Walasek, Sidharth K Sethi, Velibor Tasic, Franca Anglani, Maria Addis, Anna Wasilewska, Maria Szczepańska, Krzysztof Pawlaczyk, Przemysław Sikora, Michael Ludwig.   

Abstract

BACKGROUND: The oculocerebrorenal syndrome of Lowe (OCRL) is a rare X-linked multi-systemic disorder, almost always characterized by the triad of congenital cataract, cognitive and behavioral impairment and a proximal tubulopathy.
METHODS: Twenty-eight novel patients with suspected Lowe syndrome were studied.
RESULTS: All patients carried OCRL gene defects with mutational hot spots at CpG dinucleotides. Mutations previously unknown in Lowe syndrome were observed in ten of the 28 patients, and carriership was identified in 30.4 % of the mothers investigated. Mapping the exact breakpoints of a complete OCRL gene deletion revealed involvement of several flanking repeat elements. We noted a similar pattern of documented clinically relevant symptoms, and even though the patient cohort comprised relatively young patients, 32 % of these patients already showed advanced chronic kidney disease. Thrombocytopenia was seen in several patients, and hyperosmia and/or hyperacusis were reported recurrently. A p.Asp523Asn mutation in a Polish patient, associated with the typical cerebrorenal spectrum but with late cataract (10 year), was also evident in two milder affected Italian brothers with ocular involvement of similar progression.
CONCLUSIONS: We have identified clinical features in 28 patients with suspected Lowe syndrome that had not been recognized in Lowe syndrome prior to our study. We also provide further evidence that OCRL mutations cause a phenotypic continuum with selective and/or time-dependent organ involvement. At least some of these mutants might exhibit a genotype-phenotype correlation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25480730     DOI: 10.1007/s00467-014-3013-2

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  45 in total

1.  Oligogyric microcephaly.

Authors:  F A Hanefeld
Journal:  Neuropediatrics       Date:  1999-04       Impact factor: 1.947

2.  Carbamazepine-induced thrombocytopenia.

Authors:  Ali T Taher; Maher Arabi; Hassan Sibai; Wasim Nasreddine; Zaher K Otrock; Khaled M Musallam; Ahmad Beydoun
Journal:  Blood Cells Mol Dis       Date:  2012-02-02       Impact factor: 3.039

3.  Periventricular white matter cystic lesions in Lowe (oculocerebrorenal) syndrome. A new MR finding.

Authors:  L A Demmer; F J Wippold; S B Dowton
Journal:  Pediatr Radiol       Date:  1992

4.  Physical mapping and genomic structure of the Lowe syndrome gene OCRL1.

Authors:  R L Nussbaum; B M Orrison; P A Jänne; L Charnas; A C Chinault
Journal:  Hum Genet       Date:  1997-02       Impact factor: 4.132

5.  Identification of a novel deletion of the entire OCRL1 gene detected by FISH analysis in a family with Lowe syndrome.

Authors:  J Peverall; E Edkins; J Goldblatt; A Murch
Journal:  Clin Genet       Date:  2000-12       Impact factor: 4.438

6.  Unusual renal features of Lowe syndrome in a mildly affected boy.

Authors:  A Gropman; S Levin; L Yao; T Lin; S Suchy; S Sabnis; D Hadley; R Nussbaum
Journal:  Am J Med Genet       Date:  2000-12-18

7.  [Clinical findings in a patient with Lowe syndrome and a splice site mutation in the OCRL1 gene].

Authors:  C N Keilhauer; A Gal; J E Sold; J Zimmermann; K-O Netzer; L Schramm
Journal:  Klin Monbl Augenheilkd       Date:  2007-03       Impact factor: 0.700

8.  Renal phenotype in Lowe Syndrome: a selective proximal tubular dysfunction.

Authors:  Detlef Bockenhauer; Arend Bokenkamp; William van't Hoff; Elena Levtchenko; Joana E Kist-van Holthe; Velibor Tasic; Michael Ludwig
Journal:  Clin J Am Soc Nephrol       Date:  2008-05-14       Impact factor: 8.237

9.  Lowe syndrome: a single center's experience in Korea.

Authors:  Hyun-Kyung Kim; Ja Hye Kim; Yoo-Mi Kim; Gu-Hwan Kim; Beom Hee Lee; Jin-Ho Choi; Han-Wook Yoo
Journal:  Korean J Pediatr       Date:  2014-03-31

10.  A role of OCRL in clathrin-coated pit dynamics and uncoating revealed by studies of Lowe syndrome cells.

Authors:  Ramiro Nández; Daniel M Balkin; Mirko Messa; Liang Liang; Summer Paradise; Heather Czapla; Marco Y Hein; James S Duncan; Matthias Mann; Pietro De Camilli
Journal:  Elife       Date:  2014-08-08       Impact factor: 8.140

View more
  16 in total

Review 1.  The 5-phosphatase OCRL in Lowe syndrome and Dent disease 2.

Authors:  Maria Antonietta De Matteis; Leopoldo Staiano; Francesco Emma; Olivier Devuyst
Journal:  Nat Rev Nephrol       Date:  2017-07-03       Impact factor: 28.314

2.  Incomplete cryptic splicing by an intronic mutation of OCRL in patients with partial phenotypes of Lowe syndrome.

Authors:  Eiji Nakano; Amine Yoshida; Yudai Miyama; Tomoo Yabuuchi; Yuko Kajiho; Shoichiro Kanda; Kenichiro Miura; Akira Oka; Yutaka Harita
Journal:  J Hum Genet       Date:  2020-05-19       Impact factor: 3.172

3.  Dent disease in Poland: what we have learned so far?

Authors:  Marcin Zaniew; Małgorzata Mizerska-Wasiak; Iga Załuska-Leśniewska; Piotr Adamczyk; Katarzyna Kiliś-Pstrusińska; Adam Haliński; Jan Zawadzki; Beata S Lipska-Ziętkiewicz; Krzysztof Pawlaczyk; Przemysław Sikora; Michael Ludwig; Maria Szczepańska
Journal:  Int Urol Nephrol       Date:  2017-08-16       Impact factor: 2.370

4.  Identification and functional characterization of a hemizygous novel intronic variant in OCRL gene causes Lowe syndrome.

Authors:  Junhui Sun; Zhongwei Zhou; Chen Weng; Chaojun Wang; Jiao Chen; Xue Feng; Ping Yu; Ming Qi
Journal:  Clin Exp Nephrol       Date:  2020-05-11       Impact factor: 2.801

5.  Lowe syndrome patient cells display mTOR- and RhoGTPase-dependent phenotypes alleviated by rapamycin and statins.

Authors:  Kayalvizhi Madhivanan; Swetha Ramadesikan; Wen-Chieh Hsieh; Mariana C Aguilar; Claudia B Hanna; Robert L Bacallao; R Claudio Aguilar
Journal:  Hum Mol Genet       Date:  2020-06-27       Impact factor: 6.150

Review 6.  The oculocerebrorenal syndrome of Lowe: an update.

Authors:  Arend Bökenkamp; Michael Ludwig
Journal:  Pediatr Nephrol       Date:  2016-03-24       Impact factor: 3.714

7.  Exome-first approach identified a novel gloss deletion associated with Lowe syndrome.

Authors:  Miki Watanabe; Ryuji Nakagawa; Tomohiro Kohmoto; Takuya Naruto; Ken-Ichi Suga; Aya Goji; Hideaki Horikawa; Kiyoshi Masuda; Shoji Kagami; Issei Imoto
Journal:  Hum Genome Var       Date:  2016-11-10

8.  Splicing Analysis of Exonic OCRL Mutations Causing Lowe Syndrome or Dent-2 Disease.

Authors:  Lorena Suarez-Artiles; Ana Perdomo-Ramirez; Elena Ramos-Trujillo; Felix Claverie-Martin
Journal:  Genes (Basel)       Date:  2018-01-04       Impact factor: 4.096

9.  Ocular Pathology of Oculocerebrorenal Syndrome of Lowe: Novel Mutations and Genotype-Phenotype Analysis.

Authors:  Emilie Song; Na Luo; Jorge A Alvarado; Maria Lim; Cathleen Walnuss; Daniel Neely; Dan Spandau; Alireza Ghaffarieh; Yang Sun
Journal:  Sci Rep       Date:  2017-05-04       Impact factor: 4.379

10.  Kidney-differentiated cells derived from Lowe Syndrome patient's iPSCs show ciliogenesis defects and Six2 retention at the Golgi complex.

Authors:  Wen-Chieh Hsieh; Swetha Ramadesikan; Donna Fekete; Ruben Claudio Aguilar
Journal:  PLoS One       Date:  2018-02-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.